About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal

Clinicaltrials.gov identifier NCT03938285

Recruitment Status Active, not recruiting

First Posted May 6, 2019

Last update posted March 13, 2020

Study Description

Brief summary:

Conventional hemodialysis is essential for the treatment of ESRD patients by reducing serum concentration of uremic toxins and correcting fluid overload. Nevertheless, HD removes almost exclusively low-range uremic toxins. Convective methods might reduce complications associated to molecules of medium-range molecular weight. On-Line Hemodiafiltration (OL-HDF) is the result of the combination between convection and diffusion, this modality allows better clearence of middle-range molecules, and protein bound molecules with better hemodynamic tolerance, but at higher cost. In order to solve this problem the middle cut-off membranes were developed, achieving cleareance of molecules between 15,000 to 40,000 Da with low albumin loss. To our knowledge no study has ever evaluated the use of middle cut-off membranes on OL-HDF. This is a prospective, experimental study which will include 12 patients with ESRD that receive OL-HDF treatment on the National Institute of Cardiology "Ignacio Chavez" OL-HDF Unit. They will be divided in 4 groups: high flux HD, extended HD (HDx), OL-HDF, and OL-HDF with medium cut-off membrane.

  • Condition or Disease:Hemodiafiltration
    Chronic Kidney Disease Requiring Chronic Dialysis
  • Intervention/Treatment: Other: Theranova 400 membrane
    Other: FxCordiax 120 membrane
  • Phase: N/A
Detailed Description

Introduction: The Kidney Disease Improved Global Outcomes (KDIGO) defines Chronic Kidney Disease (CKD), as a decline of the glomerular filtration rate (GFR) below 60 mL/min/1.72 m2SC, associated with structural or functional abnormalities in a period greater than three months. CKD it's classified in 5 stages based con GFR and albuminuria . Stage 5 is considered the end stage, and it's also known as End Stage Renal Disease (ESRD), in this stage usually the patients require some kind of renal function replacement (RFR), otherwise CKD will cause the death of the patient. In Mexico the principal cause of CKD is Type 2 Diabetes Mellitus (DM2), closely followed by Systemic Arterial Hypertension (SAH), according to the 2012 National Survey of Health and Nutrition (ENSANUT) from Mexico there are 6.4 million adults with DM2, and 22.4 million adults with SAH. In Mexico the prevalence of patients currently receiving RFR it's unknown, but based in different sources we estimate that 129 thousand patients have ESRD, and only 60 thousand receive some kind of RFR therapy. In Mexico (based on data published by the Mexican Institute of Social Security), 41% of the dialysis patients are on hemodialysis (HD). ESRD patients on HD have a greater incidence of cardiovascular outcomes which cause an important impact on survival. This increase on cardiovascular outcomes can be explained by the high prevalence in this population of type 2 diabetes mellitus, and hypertension, as well as adverse outcomes associated with uremia such as chronic inflammation, and bone mineral disease vascular calcifications. Uremic toxins are clasiffied according to their molecular weight in low-range molecules (< 500 Da), middle-range molecules (500 Da - 60 kDa), hydrosoluble molecules, and protein bound molecules. Conventional hemodialysis is essential for the treatment of ESRD patients by reducing serum concentration of uremic toxins and correcting fluid overload. Nevertheless, HD removes almost exclusively low-range uremic toxins. Convective methods might reduce complications associated to molecules of medium-range molecular weight. On-Line Hemodiafiltration (OL-HDF) is the result of the combination between convection and diffusion, this modality allows better clearence of middle-range molecules, and protein bound molecules with better hemodinamic tolerance. The ES-HOL study showed that OL-HDF with post-filter sustitution patients had lower mortality in comparision with conventional HD. Convection can be poorly efficient when there´s disturbances on blood flow, time of dialysis, and low dialyser quality, to solve this kind of issues newer dialysers with better cut-offs had been developed, with this new dialysers one can achieve better clearence and greater sustitution volumes. This new dialysers allow clearence of middle-range and protein bound molecules like inflamatory mediators in sepsis, and light weigth chain immunoglobulins. Nevertheless this new dialysers cause high protein loss. In order to solve this problem the middle cut-off membranes were developed, achieving cleareance of molecules between 15,000 to 40,000 Da with low albumin loss. Recently our knowledge on uremic toxins has grown importantly, this increase in knowledge is due in part to the creation of international collaboration groups such as the European Uremic Toxin Work Group (EuTOX), which has recently described over 130 uremic toxins. Also urea metabolomics had made important contributions describing the metabolism of uremic toxins in plasma. One study used metabolomics to evaluated over 80 HD sessions, showing an important description of the metabolism of uremic toxins. To our knowledge no study has ever evaluated the use of middle cut-off membranes on OL-HDF. This study aimes to show that the combination of OL-HDF with middle cut-off membranes can achieve a higher cleareance of middle-bound molecules in comparison to regular OL-HDF with out affecting the nutritional status of the patients. Study design This is a prospective, experimental study which will include 12 patients with ESRD that receive OL-HDF treatment on the National Institute of Cardiology "Ignacio Chavez" OL-HDF Unit. Inclusion Criteria: - Age greater or equal to 18 years. - Patients that receive OL-HDF three times per week. - Patients with no residual uresis. - Hemoglobin greater that 7 g/L. - Patients that can exercise during treatment. - Patients must sign informed consent. Exclusion Criteria: - Age less tan 18. - Presence of residual uresis. - Hb less that 7 g/L. - Patients incapable of exercising during dialysis. Elimination Criteria: - Hospitalization of any cause during the study. - Patients incapable of finishing a dialysis session. Methods: 12 patients will be included, they will be divided in 4 groups: high flux HD, extended HD (HDx), OL-HDF, and OL-HDF with medium cut-off membrane. All sessions will be performed in a 5008S CorDiax that enables HD and OL-HDF, we will use an FX CorDiax 80 dializer (effective area 1.8 m2) for OL-HDF and conventional HD, and the Theranova 400 dializer (effective area 1.7 m2)for OL-HDF with medium cut-off membrane, and HDx. Every patient will be in each of the 4 groups, and they will receive 3 sessions in each group. Every session will have a duration of 240 minutes with a Qb of 300 mL/min. Blood samples will be drawn in every session at the following time points 5, 30, 60, 120 180, and 240 minutes, every blood sample will consist of 4-6 mL of EDTA plasma; this volumen would include 0.5 mL for biobanking, blood will be drawn from the arterial, and venous outlet, and a dialysate sample will be drawn in every time point. Samples will we packed, refrigerated and send to the Renal Research institute Lab, for uremic toxins metabolomics analysis, as well as middle-range uremic molecules, such as Beta 2 mycroglobulin, albumin, vitamin B12, myoglobin, Cystatin C, Urea Nitrogen, and Uric Acid. Every patient will have a full nutritional assesment before the first session, and after the third session of every modality; the assesment will include electric bioimpedance for determination of ECW/TBW, and phase angle, dinamometry, nutritional plan, and MIS (Malnutrition Inflammation Score) score. Statistical Analysis: For statistical analysis we will use the software STATA 13.0. Quantitative variables will be analized with Shapiro-Wilk, Student T will be used for group comparations. We will consider a p value of significance of less than 0.05.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 12 participants
  • Allocation: Non-Randomized
  • Intervention Model: Crossover Assignment
  • Intervention Model Description: 12 patients will be included, they will be divided in 4 groups: high flux HD, extended HD (HDx), OL-HDF, and OL-HDF with medium cut-off membrane. All sessions will be performed in a 5008S CorDiax that enables HD and OL-HDF, we will use an FX CorDiax 80 dializer (effective area 1.8 m2) for OL-HDF and conventional HD, and the Theranova 400 dializer (effective area 1.7 m2)for OL-HDF with medium cut-off membrane, and HDx. Every patient will be in each of the 4 groups, and they will receive 3 sessions in each group. Every session will have a duration of 240 minutes with a Qb of 300 mL/min. Blood samples will be drawn in every session, every blood sample will consist of 4-6 mL of EDTA plasma; this volumen would include 0.5 mL for biobanking, blood will be drawn from the arterial, and venous outlet, and a dialysate sample will be drawn in every time point.
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Rem
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: June 2019
  • Actual Study Completion Date: August 2020
Arms and interventions
Arm Intervention/treatment
Active Comparator: Extended Hemodialysis
Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
Other: Theranova 400 membrane
Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Active Comparator: On Line Hemodiafiltration with an MCO membrane
On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
Other: Theranova 400 membrane
Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Active Comparator: High Flux Hemodialysis
High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
Other: FxCordiax 120 membrane
Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Active Comparator: On Line Hemodiafiltration
On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
Other: FxCordiax 120 membrane
Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Outcome Measures
  • Primary Outcome Measures: 1. Uremic Toxins Clearance [ Time Frame: 1 month ]
    The combination of On Line Hemodiafiltration with an MCO membrane will have a better sieving coefficient for middle and protein bound molecules in comparison with other dialysis modalities.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Age greater or equal to 18 years.

- Patients that receive OL-HDF three times per week.

- Patients with no residual uresis.

- Hemoglobin greater that 7 g/L.

- Patients that can exercise during treatment.

- Patients must sign informed consent.

Exclusion Criteria:

- Age less tan 18.

- Presence of residual uresis.

- Hb less that 7 g/L.

- Patients incapable of exercising during dialysis.

Contacts and Locations
Contacts
Locations

Mexico
Instituto Nacional de Cardiologia Ignacio Chávez
Mexico City

Mexico
Instituto Nacional de Cardiología Ignacio Chávez
Mexico

Sponsors and Collaborators

Instituto Nacional de Cardiologia Ignacio Chavez

Renal Research Institute

Investigators

Principal Investigator: Magdalena Madero, MD Instituto Nacional de Cardiologia

More Information
  • Responsible Party: Instituto Nacional de Cardiologia Ignacio Chavez
  • ClinicalTrials.gov Identifier: NCT03938285 History of Changes
  • Other Study ID Numbers: PT-19-103
  • First Posted: May 6, 2019 Key Record Dates
  • Last Update Posted: March 13, 2020
  • Last Verified: March 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Plan Description: We haven´t decided what information will be disclosed on advance.
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Kidney Diseases Renal Insufficiency, Chronic